LOPRESOR SR 200 MG TABLET (EXTENDED-RELEASE)

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

METOPROLOL TARTRATE

제공처:

NOVARTIS PHARMACEUTICALS CANADA INC

ATC 코드:

C07AB02

INN (국제 이름):

METOPROLOL

복용량:

200MG

약제 형태:

TABLET (EXTENDED-RELEASE)

구성:

METOPROLOL TARTRATE 200MG

관리 경로:

ORAL

패키지 단위:

100/250

처방전 유형:

Prescription

치료 영역:

BETA-ADRENERGIC BLOCKING AGENTS

제품 요약:

Active ingredient group (AIG) number: 0111923001; AHFS:

승인 상태:

CANCELLED POST MARKET

승인 날짜:

2021-10-21

제품 특성 요약

_LOPRESOR_
SR®
_(metoprolol tartrate) _
_Page 1 of 43 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
LOPRESOR SR®
(metoprolol tartrate)
100 mg and 200 mg slow-release tablets
Beta-Adrenergic Receptor Blocking Agent
Novartis Pharmaceuticals Canada Inc.
385 Bouchard boulevard
Dorval, Quebec
H9S 1A9
Date of Initial Authorization:
June 21, 1977
Date of Revision:
February 14, 2022
Submission Control Number: 256174
LOPRESOR SR is a registered trademarks
_ _
_LOPRESOR SR_
_®_
_ (metoprolol tartrate) _
_Page 2 of 43_
RECENT MAJOR LABEL CHANGES
Not applicable
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
..........................................................................................
2
TABLE OF CONTENTS
............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1
INDICATIONS
.............................................................................................................
4
1.1 Pediatrics
......................................................................................................................
4
1.2 Geriatrics
......................................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
4
DOSAGE AND ADMINISTRATION
................................................................................
5
4.1 Dosing Considerations
.................................................................................................
5
4.2 Recommended Dose and Dosage Adjustment
............................................................ 5
4.4 Administration
.............................................................................................................
8
4.5 Miss